EMZAHH Drug Patent Profile
✉ Email this page to a colleague
When do Emzahh patents expire, and when can generic versions of Emzahh launch?
Emzahh is a drug marketed by Aurobindo Pharma and is included in one NDA.
The generic ingredient in EMZAHH is norethindrone. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the norethindrone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emzahh
A generic version of EMZAHH was approved as norethindrone by GLENMARK PHARMS LTD on July 22nd, 2010.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EMZAHH?
- What are the global sales for EMZAHH?
- What is Average Wholesale Price for EMZAHH?
Summary for EMZAHH
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 3,809 |
| Drug Prices: | Drug price information for EMZAHH |
| DailyMed Link: | EMZAHH at DailyMed |
Pharmacology for EMZAHH
| Drug Class | Progestin |
US Patents and Regulatory Information for EMZAHH
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | EMZAHH | norethindrone | TABLET;ORAL-28 | 216796-001 | Jan 6, 2023 | AB2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
